Evidence map›Paper›PMID 40942125›Full record

ArticleMolecules (Basel, Switzerland)2025

Methylation Enables Sensitive LC-MS/MS Quantification of Ciclopirox in a Mouse Pharmacokinetics Study.

Roshan Katekar, Zhengqiang Wang, Jiashu Xie

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Roshan KatekarCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0003-1374-0828
Zhengqiang WangCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-1326-5986
Jiashu XieCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-6148-5203

Funding

Development of novel antivirals against mpox (monkeypox) virusR01AI183580 · NIAID · UNIVERSITY OF MINNESOTA · PI Zhengqiang Wang, Zhilong Yang · 2024 to 2026
$2.3M
NIAID NIH HHS R01 AI183580NIH HHS 1R01AI183580-02
6 · The paper itself

Abstract

Ciclopirox (CPX), a topical antifungal agent of the N-hydroxypyridone class, has gained renewed interest for its potential anticancer, antiviral, antibacterial, and neuroprotective effects. However, due to lack of reliable validated bioanalytical methods, current insights into its pharmacokinetics profile beyond topical use remain limited. To support therapeutic repurposing, we developed and validated a rapid, sensitive LC-MS/MS method for systemic pharmacokinetic evaluation in mice. The method employs methyl derivatization of CPX's N-hydroxy group, producing methylated CPX (Me-CPX) for improved chromatographic performance which was subsequently retained on the Atlantis

Indexed as

CiclopiroxTandem Mass SpectrometryAnimalsChromatography, LiquidLiquid Chromatography-Mass SpectrometryMaleMethylationMiceReproducibility of ResultsCiclopiroxbioanalytical method validationciclopiroxLC-MS/MSpharmacokineticsprotein binding

Identifiers

PMID40942125
PMCPMC12430005

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.